

FI

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
6 February 2003 (06.02.2003)

PCT

(10) International Publication Number
WO 03/010330 A2

- (51) International Patent Classification⁷: **C12Q 1/00**
- (21) International Application Number: **PCT/EP02/08215**
- (22) International Filing Date: **23 July 2002 (23.07.2002)**
- (25) Filing Language: **English**
- (26) Publication Language: **English**
- (30) Priority Data:
01306295.5 **23 July 2001 (23.07.2001)** **EP**
- (71) Applicant (for all designated States except US): **PHARES PHARMACEUTICAL RESEARCH N.V. [NL/NL]; 14 John B Gorsiraweg, P.O. Box 3889, Curacao (AN).**
- (72) Inventors; and
- (75) Inventors/Applicants (for US only): **LEIGH, Steve [GB/CH]; PHARES Drug Delivery AG, P.O. Box, Kriegackerstrasse 30, CH-4132 MuttENZ (CH). LEIGH, Mathew, Louis, Steven [GB/CH]; Phares Drug Delivery AG, P.O. Box, Kriegackerstrasse 30, 4132 MuttENZ (CH). VAN HOOGEVEST, Peter [NL/CH]; Breitenstrasse 3, CH-4416 Bubendorf (CH). TIEMESSEN, Henricus [NL/DE]; Dinkelbergstrasse 2, 79576 Weil am Rhein (DE).**
- (74) Agents: **SCHREIBER, Wolfgang, F. et al.; Riederer Hasler & Partner, Patentanwälte AG, Elestastrasse 8, CH-7310 Bad Ragaz (CH).**
- (81) Designated States (national): **AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW.**
- (84) Designated States (regional): **ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).**
- Published:**
— *without international search report and to be republished upon receipt of that report*
- For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*



WO 03/010330 A2

(54) Title: **TEST SYSTEM AND METHOD SUITABLE FOR SELECTING TEST MATERIALS AND FORMULATIONS**

(57) Abstract: The present invention provides a test system and a method for screening lipophilic and amphipathic materials with low water solubility. It generally relates to membrane lipid suspensions or dispersions employed as a test system for obtaining desired physico-chemical and biological information relating to the interaction of materials with membrane lipids in early screens in discovery. It serves as a selection method for derivatives of a test material for optimal membrane affinity and membrane permeation and thereby predict the potential for absorption in vivo. Furthermore, it may be used in later screening in formulation development, to select a carrier for a test material or derivative to enable the highest drug load. The data obtained by using the invention in primary screening provide key information on physico-chemical properties early on which may affect drug absorption and may be more predictive than log-octanol determinations. Compared to other screening methods which utilise cell models such as liposomes and cell lines, Transmembrane Screen (TS) is a versatile miniature tool that requires minimal amounts of test substances. It is adaptable, practical, cost effective and may be used routinely in high throughput screening.

Test system and method suitable for selecting test materials and formulations

5 The present invention relates generally to a method for screening materials to obtain key physicochemical and biological data. More specifically, it relates to an improved system that is suitable for testing compounds with low water solubility, particularly for compounds that are very slightly water soluble or insoluble using a novel Transmembrane screening (TS) technique for key parameters such as solubility, membrane affinity, partitioning and transfer properties in drug discovery. The invention may also be used in formulation studies to screen and select solubilising components that may improve absorption of both novel and existing compounds. The invention is highly adaptable, mimics the properties of natural bio-membranes and allows the determination of desired physicochemical properties as well as identifying more specific information from a single screen or a series. Prior screening methods which employ membrane lipids for screening are based on either drug concentration measurements with the substrate or the surrounding aqueous phase, for determining one or other membrane property. The invention is practical, easy to perform, allows larger numbers of samples to be screened in minute amounts and thereby improve screening efficiency. The invention may also be incorporated into high throughput screening methods.

20

"Test system" comprises principally membrane lipid compositions in suspension or dispersion, optionally with other components for use with a set of procedure and experimental method for screening compounds.

25 "Activity" refers to the antagonism, agonism, inhibition, neutralisation, or other physiological effect elicited on the target or host.

30 "Material" includes any chemical or biological substance, any organic or inorganic element or compound, including nucleotide, single nucleotide, single nucleotide polymorphism and precursors thereof, or nucleotide sequence (including DNA and RNA sequences, gene, vector or construct including plasmids, or viruses), host organism (including fungi, algae, protozoa and hybridomas, eukaryotic or prokaryotic cell line or expression system or any development strain or product of that cell line or expression system), protein (including any peptide or amino acid sequence, enzyme, antibodies or pro-

tein conferring targeting properties and any fragment of a protein or a peptide enzyme or anti-body), cell cultures, drug or pro-drug, assay or reagent, or any genetic or biologic material, or membrane lipid component, or micro-organism or multi-cellular plants or components of living organisms. They may belong to product groups like pharmaceuticals, biopharmaceuticals, nutraceuticals, cosmeceuticals, components used in biotechnology, food components, veterinary and in-vitro and in-vivo diagnostic products. The expressions 'material', 'compound' and 'drug' are used interchangeably in this specification in order to more appropriately illustrate the specific applications.

"Test material" is the material that is screened for a desired physico-chemical

10 "Compound with low water solubility" covers lipophilic, hydrophobic or amphipathic compounds that require more than 10 parts of water to dissolve 1 part of the compound. It spans the definitions between sparingly soluble (from 10 to 30) to insoluble compounds (10,000 and over) but particularly very slightly soluble (from 1000 to 10'000) to insoluble (10,000 and over) as defined in USP 24.

15 "Transmembrane screen" (TS) describes experiments, procedures, and analytical methods for obtaining physico-chemical and biological data of a test material."

"Molecular association" between Test material and lipid molecules is achieved if not more
20 than 10% of un-associated test material is retained on a 200 nm polycarbonate membrane filter after filtration of at least 1:5 dilution of the mixture containing the test material with distilled water.

The recent decoding of the human genome has presented the pharmaceutical industry
25 with a wealth of opportunities to discover new protein structures related to the genome sequence. In turn these proteins serve as models to design specific molecules able to interact with the receptor proteins. At least 40 % of discovery molecules have low water solubility. The large numbers of real and virtual compounds emanating from combinatorial chemistry and computer modelling provide vast numbers of candidates for compound
30 libraries. Screening of the more promising candidates from this library for further investigation should be rapid and predictive. Therefore it is necessary to employ efficient and inexpensive screening methods to facilitate and accelerate the drug discovery and devel-

opment programs. In early testing of novel compounds for key physico-chemical properties, the limiting factors may be the absence of a fast, reliable method for predicting 'good' candidates and the small amount of the compound, often less than 10mg that may be available. Although HTS (High Throughput Screen) has been made more efficient by increasing the sensitivity and speed of spectroscopic detection methods, development of robotic techniques and the use of increasingly selective receptor/substrate combinations, it is reported that 39 % of the selected drug candidates are not screened out by the screening procedures and fail during further development because of inappropriate ADME (Absorption, distribution, metabolism, elimination properties (Kennedy, T., Drug
5 Discovery Today, 1997, 436). One reason for failure is the unreliability of current HTS methods to reliably predict 'good' and 'developable' drug candidates based on physico-chemical profiles obtained in early screens. Information on membrane interactions which may be more predictive of drug absorption is not reliable from the primary and early screens routinely used in drug discovery because of costs and time considerations.
10 Clearly, there is a need to direct closer attention in early screening towards key membrane interactions which may be more likely to influence a favourable outcome. Mainly relying on lipophilic and solubility characteristics may not be sufficient. This is evidenced by the large number of lipophilic compounds which present absorption problems due to poor membrane affinity and transfer because they are not recognised earlier.

20 It is usual to carry out the characterisation of physico-chemical properties such as lipophilicity, from log octanol/water distribution considerations. The method is cumbersome and does not relate reliably lipophilic properties to drug absorption. Where additional characterisation for membrane solubility, affinity and transfer is sought, methods such as
25 liposome chromatography, liposome partitioning, solid support lipid membranes, immobilised artificial membranes chromatography, surface plasmon resonance technology using liposome coated sensor surfaces, and assays based on micro-titer filter plates covered with lecithin have been reported. The methods may be incorporated into high throughput screens but compared to simple log octanol determinations, the screens are expensive,
30 time consuming and require sophisticated detection and analytical equipment to determine very low concentrations of lipophilic drugs. Therefore they may be difficult to justify for early screening where high throughput, speed, efficiency and low costs are important considerations. Typical methods to screen for membrane affinity which use lipid mem-

branes are; phospholipid with membrane proteins in IAM-HPLC (US 4,927,879 and US 4,931,498); bead based lipid systems (Loidl-Stahlofen. A et al. J. Pharma Sci. 90(5), 2001, 597-604); chromatographic system described in US-A-5,707,873; cubic phases (Engström S. et al., Eur. J. Pharm Sci. 8 (1999) 243-254; SPR biosensors (Danelian E. et al., Journal of Medicinal Chemistry, 2000, Vol. 43, No. 11, 2083-2086). In general, the prior art on lipid based systems that may be used to screen for membrane interaction of materials with low water solubility is concerned mostly with membrane affinity and not so much with transfer or permeability. Transfer in this context refers to the passive diffusion of the compound into or between membrane structures. Notably, the disclosures teach away from the use of liposomes and other model lipid particles for routine screens as the methods of preparation are thought to be inconvenient and add to costs and decrease efficiency.

Another major limitation with screening methods that may provide more useful information early on relating to membrane affinity and transfer concerns the requirement for the compound to be present in solution in the aqueous phase to partition/transfer into the biological membrane or cell model during screening. This may be difficult because of the poor water solubility unless organic solvents are used. For compounds that are very slightly soluble or water insoluble, the concentration in the surrounding perfusion medium may not be sufficient to facilitate partitioning because of low transmembrane gradients. Therefore the small amount of drug able to be detected in the membranes and internal aqueous compartments may require extremely sensitive analytical methods. Other techniques require separation of the reactants/components after incubation to determine free drug concentrations in the external aqueous medium.

A few of the shortcomings of typical screening methods which limit their use in routine screens using artificial cells and model membranes is discussed below.

The IAM (immobilised artificial membrane) -HPLC method is characterised by the use of HPLC column material covalently coated with a phospholipid monolayer. Affinity determination of a compound for the lipid mono-layer is estimated from the retention time of the drug in solution in the mobile phase. This procedure is therefore of limited use since solvents need to be used which may be detrimental to the monolayer. Therefore, only lipophilic compounds soluble in PBS at 0.1 to 1 mg/ml or in methanol can be tested

(Stewart B.H. and Chan O.H. J. Pharm Sci. 1998 (87),12, 1471-1478). Only lipophilic compounds within this solubility range can be tested. In addition, the method only provides an estimate of the affinity of the drug for the lipid mono-layer. Information on transmembrane permeability across multiple bi-layers is not obtained. In practice, the mono-layer
5 does not mimic a natural membrane sufficiently since the latter is composed of more than a single bi-layer.

The bead-based assay method, sold under the trade mark Transil® involves multiple steps for screening compounds using a single lipid bilayer non covalently coated on a
10 modified surface of silica or polymer beads. The beads are suspended in buffer solutions and added to different dilutions of drug in DMSO in filter well plates. After incubation, the beads are separated by fast filtration and the filtrate analysed by HPLC for free drug. The difference between the drug concentration in the reference and the filtrate gives the amount of bound material. The method does not mimic natural bi-layer membranes be-
15 cause the inner mono-layer which binds to the bead surface may be perturbed and comparisons with permeability across bi-layers may not be reliable. Furthermore, the aggregation state of the material inside the membrane is not known because only the filtrate is considered. Only a fraction of dissolved material will be bound to the lipid mono layer. Since the compound has poor water solubility, the small difference between two very low
20 values gives a high margin of error. If increased amounts of drug are added to the bead suspension, precipitated drug particles are likely to be retained on the beads and may not appear in the filtrate. Alternatively, if the particle size of the precipitated drug is much smaller than the bead size, the colloidal particles may be in the filtrate and give equally misleading information. For these reasons, Transil® can only be used for lipophilic com-
25 pounds with known and sufficient water solubility and may not be suitable for use in routine screening where solubility profiles are largely undetermined and very low water solubility may prevail.

US-A-5,707,873 describes a method of assessing mixed lipid transport properties of a
30 compound. The method provides for a mixed lipid composition which incorporates a drug as colloidal particles subjected to size exclusion chromatography. Drugs which elute with the mixed lipid particles are considered to have stable transport properties. The dis-

closure does relate to screening for key physico-chemical and biological properties e.g. solubility and passive transfer across membranes.

5 Cubic phases have also been described for measurement of drug partitioning into lipid bilayers in a HTS setting (Engström S. et al., Eur. J. Pharm Sci. 8 (1999) 243-254). However, the authors recognise that the lipid used, glyceryl mono-oleate is not a typical naturally occurring phospholipid bilayer. In this study, only affinity and not permeability is considered. The method requires separation of the components in the substrate and may not be easily adapted for screening small quantities of large numbers of compounds rapidly and
10 effectively.

It is therefore an object of the present invention to provide a Test system and a method for screening of compounds to establish both overall and more specific physico-chemical parameters earlier. One of the virtues in the technique is that the measurements may be carried out in the first instance on the Test system in its entirety, i.e. without separation of the components. However, if required it does not rule out the option to separate out the components after incubation to study a particular membrane interaction. Usual separation methods such as centrifugation and simple analytical filtration are normally sufficient.
15 The invention is an improved method that is suitable for testing compounds with low water solubility, in particular compounds classed as very slightly soluble and water insoluble, using a novel Transmembrane screening (TS) technique for screening desired parameters such as solubility, membrane affinity, partitioning and transfer properties in drug discovery. It is particularly suitable for screening small quantities of large numbers
20 of compounds rapidly and effectively. The invention may also be used in formulation studies with optionally other components to identify and select components that may improve absorption of novel and existing compounds. By using different types of membrane lipids and optionally other components to form lipid structures and by varying the test conditions more comparative information on affinity and transfer properties may be
25 obtained from the screen and predict more closely in vivo absorption characteristics than simple log octanol/ water determinations. The invention is particularly suitable for throughput screening of novel compounds and in formulation screens to improve the delivery of existing compounds. The invention may be used for a single determination in
30

a single container e.g. test tube or preferably in series, e.g. in well plates with multiple micro-reservoirs.

The invention is particularly suitable to screen active test materials which are very slightly water soluble (i.e. 1 in 1000 and over) for,

- membrane affinity,
- membrane permeability, transfer
- membrane lipid compatibility.

Accordingly, the invention provides for a Test system comprising at least one membrane lipid component, preferably a phospholipid dispersed in an aqueous medium, optionally with other excipients. Depending on the components used, the invention may mimic many of the properties of natural membranes, offers the possibility to use asymmetric test conditions, allows rapid and efficient screening measurements with the possibility for automation. The invention compares to a practical miniature tool and allows the use of minimal amounts of test materials, typically below 100mg, possibly below 5mg quantities for each screen in single or multiple cells, in single or preferably in a series of tests. The volume in each container may be between 10 microlitres to about 1000 microlitres or more, preferably between 50 to 500 microlitres. However, this should not be a limiting factor and depending on the compound and method of analysis smaller or larger volumes may be used. The containers for carrying out the screen may be U-V cells, test tubes, micro test tubes, nephelometer tubes, micro reservoirs such as well plates or any suitable vessel that may be used for high speed, robotic or automated handling. The test may be performed sequentially or in parallel for high throughput. Well plates are particularly preferred because of the large numbers of micro-reservoirs available for performing a series of separate tests using a single plate. The results from one well plate represent the data from a single screen and provides the desired information on key membrane interactions.

To carry out the screen for membrane affinity, a range of concentrations for the test material is dissolved in a minimum volume of one or more suitable organic solvent. Each solution is added to the container or micro-reservoirs e.g. well plate, containing a Test System. After equilibration, the well plate is examined for presence of precipitated material to determine membrane interaction by UV or any suitable analytical method. The point of

inflection on a lipid/drug ratio 'vs' transmission (turbidity) plot relates to optimum membrane affinity for the particular Test system. A series of graphs from different Test systems may be drawn and the data compared. Similarly, time/transmission and membrane transfer plots may be obtained on the compound or different compounds and
5 varying and permutating different Test systems. Furthermore, the screening or analytical conditions may be varied to obtain additional information relating more closely to specific in vivo transfer. Therefore a large number of variables may be screened with a small amount of Test material in a single well plate. Comparative data from a series of tests performed simultaneously in each plate may provide comprehensive information to characterise the test material more reliably. Turnaround time for each screen is extremely rapid.
10

When bilayer forming membrane lipid compositions are used to form unilamellar vesicles with particle size between 20 and 100 nm, the screening yields information on the membrane interaction with membranes comprising typical single lipid bilayer .
15

When bilayer forming membrane lipid compositions are used in which the lipid is dispersed in water to form multilamellar vesicles within a size range of about 50 nm to about 20 μ m, the screening yields information on the membrane interaction e.g. affinity and membrane permeation of the test material through model cells with alternating lipid bi-layers.
20

In another variant, the invention allows high throughput screening using lipid suspensions where the internal aqueous domains comprise a medium that is different from the external medium (e.g pH, water soluble proteins). Thus, the suspension more closely
25 mimics the situation in the stomach and duodenum where pH differences across the membrane can exist.

When aqueous micellar lipid dispersions are used which comprise mono-acyl membrane lipids or mixtures of mono and di-acyl membrane lipids in the Test system, the screening
30 yields information on solubilisation of lipophilic materials in the intestines prior to absorption.

A further aspect of the invention relates to evaluating membrane lipid interaction in terms of aggregation state, molecular dispersion and stability of the complex formed by the Test system. Preferably, the Test system disperses in water and is optically clear initially and/or allows reproducible transmission of light in its entirety, which can be measured using an appropriate analytical method. All that is needed after incubation is qualitative visual inspection of the turbidity of the well plate or other micro reservoirs to obtain the required information. Optionally if required, simple centrifugation or filtration may be used and quantitative analysis for more specific physico-chemical data may be made using image analysers, light microscopic observation and spectrophotometric analysis in the UV-Vis region or IR, preferably NIR region or by fluorescence as determined by the physico-chemical properties of the test material. Molecular association of the active material in the Test system may be determined by means of automated sequential filtration through a 0.2 μm pores size filter plate. It should be clearly understood that the Test system in the micro-reservoirs comprising the complex formed after incubation may be introduced to biological cell models and cell lines for screening for desired biological properties. In these instances these may be regarded as alternative detection methods.

The Test system may be used to assess the membrane interaction properties of compounds with unknown solubility in initial drug discovery. The main requirement in utilising the invention is for the material to have sufficient solubility in minimum quantities of water miscible solvents with optionally small amounts of an aqueous medium and/or surfactants. Preferably the compound is in solution, but may be in suspension.

The present invention provides a reliable and reproducible method for screening for solubility and membrane lipid interactions of compounds having low water solubility by a) preparing a solution or suspension of a compound having low water solubility in at least one water miscible organic liquid with optionally small amounts of an aqueous medium and/or excipients.

b) preparing a Test system comprising at least one membrane lipid i) in homogeneous suspension in water or an aqueous medium ii) optionally other excipients and components

c) mixing a solution of said compound with low water solubility with at least one of said compositions with at least one membrane lipid in suspension;

and d) analysing the resultant mixture for desired physico-chemical and or biological data.

5

Preferably the screen is performed in e.g. 96 (or less) or 384 (or more) well plates to enable multiple testing. However, the apparatus or container used for the screen or the volumes used are not limiting factors and the invention may be incorporated into most high throughput screening procedures.

10

The present invention provides a Test system and the use thereof, to screen for interaction of materials with lipophilic and amphiphilic characteristics under controlled conditions such as temperature and equilibration time. The invention includes particularly the use of homogeneous suspensions and dispersions of diacyl membrane lipids, diacyl membrane lipids enriched with monoacyl membrane lipids or monoacyl lipids alone. The invention includes the use of unilamellar phospholipid vesicles suspensions to assess lipid bilayer affinity. It covers the use of multilamellar vesicles to assess both bilayer affinity and bilayer permeability characteristics of test materials. It also includes non vesicular membrane lipid structures such as micelles, mixed micelles and microemulsions etc. to assess permeability and transfer. The Test system further includes optionally, other pharmaceutically acceptable solubilising components including but not limited to e.g. cyclodextrins and derivatives thereof, polymers and surfactants.

15

20


25

30

The membrane lipid components for the Test system may be prepared as a stock dispersion. The preferred lipid type used is phosphatidylcholine (PC). Further preferred lipids and lipid mixtures include either a mixture of diacyl (PC) and monoacyl (MAPC) components in a ratio of 1:20 to 20:1, preferably 1:10 to 10:1, most preferably 1:5 to 5:1. Most preferred diacyl phosphatidylcholines are soy PC, Egg PC, POPC (1-palmitoyl, 2-oleoylphosphatidylcholine), OOPC (1,2 dioleoylphosphatidylcholine) and partially hydrogenated Soy and Egg PC reaching a similar fatty acid composition as POPC. Also negatively charged synthetic, semi-synthetic or naturally occurring phosphatidylserines,

preferably 1,2 di-oleoylphosphatidylserine, phosphatidic acids, phosphatidylinositols, phosphatidylglycerol, preferably 1,2 dioleoylphosphatidylglycerol and 1-palmitoyl,2-oleoyl phosphatidylglycerol, Egg derived PG and soy derived PG may be used. Most preferred monoacyl counterparts of the above mentioned diacyllipids include enzyme modified (Phospholipase A2) soy PC, followed by Egg PC, 1 -palmitoyl PC, 1 oleoyl PC, 1-stearoyl PC. Preferred suspensions or dispersions of membrane lipids in water contain between 0.1 to 20 % w/w preferably between 0.1% to 5% and most preferably between 0.25% to 2.0%. Unilamellar structure should preferably have a particle size smaller than about 100 nm. Multilamellar structures should preferably have a particle size ranging from about 50 nm to 20 µm with less than 30 % of the lipid located in the outer membrane of the multilamellar structure.

The Test system comprises at least one solubilising component, preferably at least one phospholipid of the formula



wherein

R₁ represents C₁₀-C₂₀acyl;

R₂ represents hydrogen or C₁₀-C₂₀acyl;

R₃ represents hydrogen, 2-trimethylamino-1-ethyl, 2-amino-1-ethyl, C₁-C₄alkyl, C₁-C₅alkyl substituted by carboxy, C₂-C₅alkyl substituted by carboxy and hydroxy, C₂-C₅alkyl substituted by carboxy and amino, an inositol group or a glyceryl group or a salt of such compound.

Other examples of membrane lipids are cardiolipin, phosphatidylethanolamines, sphingomyelin, cerebroside, glycolipids, ceramides, cholesterol and cholesterol derivatives. These membrane lipids may be purified or crude cell membrane extracts containing other membrane components derived from natural membranes and barriers like brush border membranes, astrocytes, skin cells, epithelial cells etc. natural plant or animal or microbiological sources, synthesised or partially synthesised and hydrogenated, including polyethylene glycol (PEG) derived diacyl and monoacyl equivalents. Wherever possible,

the same components should be used for screening and for delivery in order to minimise the risks from changes during development. Membrane lipids such as phospholipids are widely used excipients and are preferred because of their safety and regulatory features.

- 5 Examples of suitable organic solvents to dissolve the drug include but are not limited to: methanol, ethanol, 96% ethanol, tert-butanol, absolute glycerol, propylene glycol, ethyl lactate, polyethylene glycol 300, polyethylene glycol 400, 1,3 butandiol, succinic acid diethyl ester, triethyl citrate, dibutyl sebacate, dimethyl acetamide, DMSO, DMF, glycerine-formal, glycofurol (tetraglycol), isopropanol, transcitol, lactic acid butyl ester, N-methylpyrrolidone, solketol, propylene carbonate, propylene glycol diacetate, tetrahydrofurfuryl alcohol, diethylene glycol mono ethyl ether, triacetin.
- 10

- Examples of additional excipients suitable for Test system compositions include but are not limited to: benzyl alcohol, benzyl benzoate, triglycerides, medium chain triglycerides like Miglyol 810TM, Miglyol 812TM, Miglyol 812 NTM, Miglyol 829TM, Miglyol 840TM Miglyol 8810TM, isopropyl myristate, isopropyl palmitate, ethyl oleate, (2-octyl dodecanol), bile salts, laurinsäure hexyl ester, oleic acid, ricinus oil, sesame oil, soybean oil, salts like NaCl, CaCl₂, MgCl₂, buffer components like NaH₂PO₄, Na₂HPO₄, citric acid, HCl, NaOH, Tris, imidazole, borate, cyclodextrins, sugars like lactose, glucose, mannose, sucrose, polyalcohols like mannitol, sorbitol, , anti-oxidants like alpha tocopherol acetate, ascorbyl palmitate, antimicrobial preservatives like methyl and butyl parabene, thiomersal, sodium azide.
- 15
- 20

The Test system may be prepared as follows:

- A homogeneous suspension or dispersion containing, at least one membrane lipid and optionally other excipient(s) is prepared by suspending the lipid in an aqueous medium.
- 25 The aqueous medium may be buffer solutions, D2O, water and optionally may contain minor amounts of water miscible organic liquid. A suspension comprising unilamellar vesicles with diacyl PC is prepared by suspending the lipid in water followed by high shear/high pressure homogenisation until the required particle size, e.g. below 100 nm is obtained. After sterile filtration the suspension is filled into glass vials and closed with rubber stoppers and aluminium caps. Multilamellar vesicles may be prepared from lyophilisates of POPC or partially hydrogenated soy or egg PC optionally containing up to
- 30

30 weight parts OOPS (1,2 dioleoylphosphatidylserine) or other negatively charged lipid and optionally containing cholesterol lyophilised from tert-butanol according to US-A-4,370,349 by addition of a predetermined volume of saline solution. Alternatively, multi-lamellar liposomes may be prepared by spraying organic solution on sugar or polyalcohol crystals followed by removal of the solvent under reduced pressure and hydration of the resulting lipid containing solid matrix. Any preparation method that is suitable may be used to form vesicular or non vesicular membrane lipid structures.

The following examples illustrate the invention using test materials of well characterised, known substances having poor water solubility as surrogate compounds typically screened in discovery or in later formulation testing, to obtain physico-chemical and biological data relating to membrane affinity and solubility.

Example 1

This example represents a novel compound that is screened for overall membrane affinity properties initially using the Test system. In this example the interaction of a lipophilic Vitronectin receptor antagonist with M.W of 523 and Log P (octanol/water) 2.3, is screened using a Test system comprising membrane lipid in a 96 disposable plastic well plate (Dynatech).

a) Six Test systems are prepared as described, comprising homogeneous aqueous suspensions comprising 0.5% or 1.0 % by weight of,

i) VP 200 (a lipid mixture comprising 98% diacyl phospholipid from soy bean phospholipid

ii) VP 805 (blend containing 35% diacyl with 65 % mono-acyl phospholipid)

iii) VP 814 (10% diacyl phospholipid with 90 % mono-acyl phospholipid, specially supplied by Lipoid KG, FRG).

b) A stock solution of 10mg Vitronectin receptor antagonist/ml is prepared in DMSO and serial dilutions made with DMSO to concentrations of 5, 2.5, 1, 0.4, 0.2, 0.1 and 0.05mg/ml.

c) 200 µl of each of the Test system from a) is dispensed into the well plate followed by 25 µl of the drug solution from b).

d) The well plate is shaken for 20 seconds and then immediately inspected visually or turbidity assessed at 690 nm at room temperature and without further separation or filtration.

The results show that in the Test system (i) comprising 0.5 % of the compound, no increase in turbidity is observed up to 16:1 lipid/drug w/w ratio. It suggests that at this level, the drug is complexed to lipid bilayers. The affinity of the drug for bilayer forming membrane lipid prevents precipitation of the drug. Lower lipid/drug ratios show the presence of precipitated drug. The point at which drug precipitation starts to occur quantifies the drug/membrane lipid interaction. According to this experiment mixed micelles (VP 805 and VP814) show less affinity for this drug since precipitation of the drug occurs at higher lipid/drug ratios. The results are illustrated in Fig. 1.

The screen was performed in triplicate and similar results were obtained, illustrating the reproducibility of the Test system to characterise the overall membrane affinity of compounds. It should be understood that optionally, the suspensions in the well plate may be centrifuged or filtered if more detailed information on specific interaction e.g. free drug is required.

Example 2

This provides a typical example of an anti-microbial agent screened for optimum activity in formulation studies.

- a) A test system comprising 2.5 % VP 200 or VP 805 by weight is prepared as in example 1.
- b) Solution of 80mg Clotrimazole/ml are prepared in DMSO and ethanol. Serial dilutions are made to concentrations of 60, 40, 20, 10, 5, 1, 0.4 mg/ml for both solvents.
- c) 25µl of each of the solution from b) is dispensed into the 96 well plate containing 200µl of each Test system from a), as in example 1.
- d) The well plate is incubated and analysed as in example 1.

After incubation, the results show that when the ethanolic Clotrimazole solutions are added to the Test systems containing VP 200 and VP 805, no change in turbidity is observed up to 20:1 lipid/drug w/w ratio. This suggests at this lipid/drug ratio the drug has sufficient affinity for either lipid bilayers composed of VP 200 or mixed lipid dispersions comprising VP 805 that precipitation is prevented. Lower lipid/drug ratios show the presence of precipitated drug. According to this screen, the higher turbidity of the Test

stations comprising VP 805 compared to VP200 at 10:1 or lower lipid to drug ratios suggest that Clotrimazole may have higher affinity for VP 200 than VP 805. When DMSO solutions of Clotrimazole are used (VP 200d and VP 805d) the drug starts to precipitate at 20:1 lipid/drug ratio. However the higher affinity of the compound for bilayer membrane structures compared to mixed micelle structures is also evident. The results are illustrated in Fig. 2.

If further information is required on the nature of the affinity and binding characteristics from the initial coarse screen, the Test systems may be fine tuned by using different types of lipid and other components to examine the binding characteristics and transfer properties without detracting from the principle of the invention. In step c), the reservoirs used for the screen may be seeded culture plates to screen for anti-fungal properties. Alternatively in place of culture plates, Caco2 cell lines may be used to obtain biological data. In addition, the suspensions in the well plate may be centrifuged/filtered prior to incubation in cup-plates or other detection equipment to identify or compare activities.

Example 3

This is an example of a highly lipophilic compound to assess membrane properties.

a) 0.05 % by weight of a homogeneous aqueous suspension comprising VP 200, VP 805 or VP815 is prepared.

b) A stock solution of 60 mg Cyclosporin A/ml is prepared in DMSO and ethanol. Serial dilutions are made to 40, 20, 10, 5, 2.5, 1, 0.4, 0.2, 0.1 and 0.05 mg/ml.

c) 25µl of drug solution from b) is dispensed into the 96 well plate with 200µl of lipid dispersion from a) in each micro-reservoir.

d) The well plate is incubated and analysed as in Example 1.

Data from the screen show that regardless of the lipid type and solvent used to dissolve cyclosporin, down to as low as 2:1 lipid/drug w/w ratio, there is no increase in the turbidity observed (Fig. 3). This means that at this ratio the amount of drug has sufficient affinity for membranes composed of VP 200 (bilayers) or VP 805 (mixed micelles) or VP 815 (micelles) to prevent precipitation. Lower lipid/drug ratios show the presence of precipitated drug. The ratio at which drug precipitation starts to occur is therefore an indication of drug/ membrane lipid interaction. According to the screen, cyclosporin A shows a

very high affinity for membrane lipids compared to the drugs tested in Example I and II. The results are depicted in Fig. 3.

Release or reverse transfer of the compound from the bound complex back into the surrounding medium may be examined by plotting a reverse time/concentration course.

5

The following figures illustrate the invention with reference to the above examples.

Fig. 1 illustrates the influence of lipid/drug ratio on the turbidity of several drug lipid mixtures;

Fig. 2 illustrates the influence of lipid/Clotrimazole ratio on the turbidity of several drug
10 lipid mixtures; and


Fig. 3 illustrates Influence of lipid/cyclosporin A ratio on the turbidity of several drug lipid mixtures.

The present invention provides a test system and a method for screening lipophilic and
15 amphipathic materials with low water solubility. It generally relates to membrane lipid suspensions or dispersions employed as a test system for obtaining desired physico-chemical and biological information relating to the interaction of materials with membrane lipids in early screens in discovery. It serves as a selection method for derivatives of a test material for optimal membrane affinity and membrane permeation and thereby
20 predict the potential for absorption in vivo. Furthermore, it may be used in later screening in formulation development, to select a carrier for a test material or derivative to enable the highest drug load. The data obtained by using the invention in primary screening provide key information on physico-chemical properties early on which may affect drug absorption and may be more predictive than log-octanol determinations. Compared to
25 other screening methods which utilise cell models such as liposomes and cell lines, Transmembrane Screen (TS) is a versatile miniature tool that requires minimal amounts of test substances. It is adaptable, practical, cost effective and may be used routinely in high throughput screening.

Claims:

1. A method suitable for screening for solubility and membrane lipid interactions of compounds comprising:
 - 5 a) preparing a solution or suspension of a compound having low water solubility in at least one water miscible organic liquid with optionally small amounts of an aqueous medium and/or excipients
 - b) preparing a Test system comprising at least one membrane lipid
 - 10 i) in homogeneous suspension in water or an aqueous medium
 - ii) optionally other excipients and components
 - c) mixing the solution or suspension of said compound having low water solubility with at least one of said compositions with at least one membrane lipid in sus-
15 pension; and
 - d) analysing the resultant mixture for desired physico-chemical and or biological data.
- 20 2. The method of claim 1, wherein the desired physico-chemical and or biological data is analysed without separation thereof at the end of the incubation period.
3. The method of claim 1, wherein the desired physico-chemical and or biological data is analysed after separation thereof at the end of the incubation period.

4. The method of any one of claims 1 - 4, wherein said at least one membrane lipid, being a phospholipid of the formula



wherein

R₁ represents C₁₀-C₂₀acyl;

R₂ represents hydrogen or C₁₀-C₂₀acyl;

R₃ represents hydrogen, 2-trimethylamino-1-ethyl, 2-amino-1-ethyl, C₁-C₄alkyl, C₁-C₅alkyl substituted by carboxy, C₂-C₅alkyl substituted by carboxy and hydroxy, C₂-C₅alkyl substituted by carboxy and amino, an inositol group or a glyceryl group or a salt of such compound.

5. The method according to any one of claims 1 - 5, wherein said screening is performed in a single container.
6. The method according to any one of claims 1 - 5, wherein said screening is carried out in one of UV-cells, test tubes, micro test tubes, nephelometer tubes, and micro-reservoirs, such as, e.g. are contained in well plates.
7. The method according to claim 7, wherein a number of screenings are performed in parallel.
8. The method according to any one of claims 1 - 8, wherein said test material is further screened in cell models, cell lines, and the like.

9. The method as claimed in any one of the preceding claims applied in high throughput screening (HTS).
10. A delivery system comprising a test material having poor water solubility using
5 membrane lipid and other components resulting from use of any of the methods.





Fig. 1

Fig. 2




Fig. 3

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
6 February 2003 (06.02.2003)

PCT

(10) International Publication Number
WO 03/010330 A3

(51) International Patent Classification⁷: **G01N 33/50**,
33/92

(21) International Application Number: PCT/EP02/08215

(22) International Filing Date: 23 July 2002 (23.07.2002)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
01306295.5 23 July 2001 (23.07.2001) EP

(71) Applicant (for all designated States except US): **PHARES
PHARMACEUTICAL RESEARCH N.V.** [NL/NL]; 14
John B Gorsiraweg, P.O. Box 3889, Curacao (AN).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **LEIGH, Steve**
[GB/CH]; PHARES Drug Delivery AG, P.O. Box, Kri-
egackerstrasse 30, CH-4132 MuttENZ (CH). **LEIGH,
Mathew, Louis, Steven** [GB/CH]; Phares Drug Delivery
AG, P.O. Box, Kriegackerstrasse 30, 4132 MuttENZ (CH).

VAN HOOGEVEST, Peter [NL/CH]; Breitenstrasse
3, CH-4416 Bubendorf (CH). **TIEMESSEN, Henricus**
[NL/DE]; Dinkelbergstrasse 2, 79576 Weil am Rhein (DE).


(74) Agents: **SCHREIBER, Wolfgang, F.** et al.; Riederer
Hasler & Partner, Patentanwälte AG, Elestastrasse 8,
CH-7310 Bad Ragaz (CH).

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,
CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW,
MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG,
SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ,
VN, YU, ZA, ZM, ZW.

(84) Designated States (*regional*): ARIPO patent (GH, GM,
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),
Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),
European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE,
ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK,
TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ,
GW, ML, MR, NE, SN, TD, TG).

[Continued on next page]

(54) Title: TEST SYSTEM AND METHOD SUITABLE FOR SELECTING TEST MATERIALS AND FORMULATIONS



(57) Abstract: The present invention provides a test system and a method for screening lipophilic and amphipathic materials with low water solubility. It generally relates to membrane lipid suspensions or dispersions employed as a test system for obtaining desired physico-chemical and biological information relating to the interaction of materials with membrane lipids in early screens in discovery. It serves as a selection method for derivatives of a test material for optimal membrane affinity and membrane permeation and thereby predict the potential for absorption in vivo. Furthermore, it may be used in later screening in formulation development, to select a carrier for a test material or derivative to enable the highest drug load. The data obtained by using the invention in primary screening provide key information on physico-chemical properties early on which may affect drug absorption and may be more predictive than log-octanol determinations. Compared to other screening methods which utilise cell models such as liposomes and cell lines, Transmembrane Screen (TS) is a versatile miniature tool that requires minimal amounts of test substances. It is adaptable, practical, cost effective and may be used routinely in high throughput screening.



Published:

— with international search report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(88) Date of publication of the international search report:

28 August 2003

BEST AVAILABLE COPY

INTERNATIONAL SEARCH REPORT

International Application No
PCT/EP 02/08215

A. CLASSIFICATION OF SUBJECT MATTER
IPC 7 G01N33/50 G01N33/92

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 7 G01N

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	<p>LOIDL-STÄHLHOFEN A., ECKERT A., HARTMANN T AND SCHÖTTNER M: "Solid-supported lipid membrane as a tool for determination of membrane affinity: high-throughput screening of a physicochemical parameter" J. PHARM. SCIENCES, vol. 90, no. 5, May 2001 (2001-05), pages 599-606, XP002232186 page 601, "Determination of membrane affinity using solid-supported lipid membranes" paragraph --- -/-</p>	1-9

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents:

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- *Z* document member of the same patent family

Date of the actual completion of the international search

25 February 2003

Date of mailing of the international search report

11/03/2003

Name and mailing address of the ISA

European Patent Office, P.B. 5618 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Jacques, P

BEST AVAILABLE COPY

INTERNATIONAL SEARCH REPORT

International Application No
PCT/EP 02/08215

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	VON CORSWANT C. AND THORÉN PER E.G.: "Solubilization of sparingly soluble active compounds in Lecithin-Based microemulsions: influence on phase behavior and microstructure" LANGMUIR, vol. 15, no. 11, 1999, pages 3710-3717, XP002188168 experimental section abstract	1-10
Y	BETAGERI G.V. AND DIPALI S.R.: "Partitioning and thermodynamic of dipyridamole in the n-octanol/buffer and liposome systems" J. PHARM PHARMACOL, vol. 45, 1993, pages 931-933, XP009006041 "Materials and Methods" section	1-9
Y	GO M-L AND NGIAM T-L: "Thermodynamics of partitioning of the antimalarial drug Mefloquine in phospholipid bilayer and bulk solvents" CHEM. PHARM. BULL., vol. 45, no. 12, 1997, pages 2055-2060, XP001145780 Experimental section	1-9
A	US 4 927 879 A (PIDGEON CHARLES) 22 May 1990 (1990-05-22) cited in the application the whole document	1-9
A	US 4 931 498 A (PIDGEON CHARLES) 5 June 1990 (1990-06-05) the whole document	1-9

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Continuation of Box I.2

Claims Nos.: 10

Present claim 10 relate to an extremely large number of possible "other components resulting from use of any of the methods". As the said components are not defined, the claim contains so many options, that a lack of clarity (and/or conciseness) within the meaning of Article 6 PCT arises to such an extent as to render a meaningful search of the claim impossible. Consequently, the search has been carried out for those parts of the application which do appear to be clear (and/or concise), namely a delivery syystem comprising a test material having poor water solubility using membrane lipid.

The applicant's attention is drawn to the fact that claims, or parts of claims, relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure.

BEST AVAILABLE COPY

INTERNATIONAL SEARCH REPORT

International application No.
PCT/EP 02/08215

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
2. ☒ Claims Nos.: 10
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
see FURTHER INFORMATION sheet PCT/ISA/210
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this International application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

BEST AVAILABLE COPY

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/EP 02/08215

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
US 4927879	A	22-05-1990	US 4931498 A	05-06-1990
			AU 3194689 A	22-09-1989
			CA 1337801 A1	26-12-1995
			EP 0408585 A1	23-01-1991
			JP 3502836 T	27-06-1991
			WO 8908130 A1	08-09-1989
US 4931498	A	05-06-1990	AU 3194689 A	22-09-1989
			CA 1337801 A1	26-12-1995
			EP 0408585 A1	23-01-1991
			JP 3502836 T	27-06-1991
			WO 8908130 A1	08-09-1989
			US 4927879 A	22-05-1990